Balyasny Asset Management
SPRY icon

Balyasny Asset Management’s ARS Pharmaceuticals SPRY Stock Holding History

Balyasny Asset Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$518K Buy
64,658
+2,906
+5% +$25K ﹤0.01% 2501
2026
Q1 		$496K Buy
+61,752
New +$592K ﹤0.01% 2367
2025
Q4 		– Sell
-246,170
Closed -$2.47M – 3521
2025
Q3 		$2.47M Sell
246,170
-82,903
-25% -$1.19M ﹤0.01% 1704
2025
Q2 		$5.74M Buy
329,073
+157,949
+92% +$2.28M 0.01% 1218
2025
Q1 		$2.15M Sell
171,124
-173,817
-50% -$2.09M ﹤0.01% 1672
2024
Q4 		$3.64M Buy
344,941
+322,423
+1,432% +$4.52M 0.01% 1419
2024
Q3 		$327K Sell
22,518
-3,817
-14% -$45.4K ﹤0.01% 2431
2024
Q2 		$224K Sell
26,335
-4,106
-13% -$36.4K ﹤0.01% 2308
2024
Q1 		$311K Buy
30,441
+13,002
+75% +$96.9K ﹤0.01% 2245
2023
Q4 		$95.6K Buy
+17,439
New +$76.4K ﹤0.01% 2386
2023
Q1 		– Sell
-11,328
Closed -$96.6K – 3118
2022
Q4 		$96.6K Buy
+11,328
New +$73.5K ﹤0.01% 2255

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Balyasny Asset Management's SPRY Position: Q2 2026 in Review

Balyasny Asset Management increased its ARS Pharmaceuticals (SPRY) stake by 4.7% in Q2 2026, buying an estimated $25K and bringing the position to 64,658 shares worth $518K. The position accounts for ﹤0.01% of the portfolio, ranked #2501.

Balyasny Asset Management first reported a position in SPRY in Q4 2022 and has held it in 11 quarters since. The position peaked at $5.74M in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Balyasny Asset Management held 64,658 shares of ARS Pharmaceuticals worth $518K as of Q2 2026.
  • Balyasny Asset Management bought 2,906 ARS Pharmaceuticals shares in Q2 2026, an estimated $25K.
  • ARS Pharmaceuticals made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #2501 holding.
  • Balyasny Asset Management first reported a position in ARS Pharmaceuticals in Q4 2022 and has held it in 11 quarters since.
  • Balyasny Asset Management's ARS Pharmaceuticals position peaked at $5.74M in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.